Tarian Pharma Achievements in 2021
Drug development achievements
- CMC: Long term stability of TAR-0520 gel at 25°C and 40°C has been confirmed
- Nonclinical: Completion of toxicology package allowing entrance in the first clinical study in cancer patients
- Clinical Pharmacology: Demonstration of skin bioavailability and pharmacological performance over 24 hours with our lead candidate TAR-0520 gel
- Clinical:Clinical sites to conduct the first study in patients selected
Intellectual Property
- Patents filed in February 2021 and have entered PCT phase in February 2022
Awards
- Tarian Pharma nominated in 2021 i-Lab contest
- Tarian Pharma obtained Eurobiomed certification